

APAP31191-A 072852.0117
PATENT

36. (AMENDED) The method of Claim 35 wherein the pharmaceutical is selected from the group consisting of colchicine, sulfapyrazone, allopurinol, piroxicam, tolmetin-sodium, idomethacin, ibuprofen, diflunisal, mefenamic acid, and mesalamine, sulindac, sulindac sulfon, saliclic acid and its derivatives thereof.

Please add the following new claims.

88. (NEW) A method comprising:

(a) administration of an oral liquid dosage form comprising:

- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
- (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
- (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

89. (NEW) The method of Claim 88 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

90. (NEW) The method of Claim 88 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, taoursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursoodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

APAP31191-A 072852.0117
PATENT

91. (NEW) The method of Claim 88 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

92. (NEW) The method of Claim 88 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

93. (NEW) The method of Claim 88 wherein the oral liquid dosage form additionally comprises a least one additional agent.

94. (NEW) The method of Claim 93 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

12 cont

95. (NEW) The method of Claim 88 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount.

96. (NEW) The method of Claim 95 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, ampmomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscamet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- α , β , γ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir-H₂SO₄, ritonavir, nelfinavir-CH₃SO₃H, saquinavir-CH₃SO₃H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyridamole, isoxsuprine-HCl, niacin, nylidhn-HCl,

APAP31191-A 072852.0117
PATENT

phentolamine, doxazosin-CH₃SO₃H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidomine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythrytol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadil, albuterol, pirbuterol, terbutaline-H₂SO₄, salmetrol, aminophylline, dyphylline, ephedrine, ethylnorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan-HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartrate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartarate, glycerin, terpiu-hydrate, colfasceril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, simvastatin, picrorrhiza kurvva, andrographis paniculata, mornga oleifera, albizzia lebeck, adhata vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO₃, miconazole, nystatin, oxiconazole-HNO₃, sulconazole-HNO₃, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrhizin, glycyrrhizic acid, betamethasone, ludrocortisone acetate, flunisolide, fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopudnol, piroxicam, tometin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds insuline, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

Q2 w/

97. (NEW) A method of increasing or decreasing the enterohepatic bile acid comprising;

NY02:358466.1

APAP31191-A 072852.0117
PATENT

(a) administration of an oral liquid dosage form comprising:

- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
- (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
- (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

Claim 97 cont
98. (NEW) The method of Claim 97 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

99. (NEW) The method of Claim 97 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, taoursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursoodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

100. (NEW) The method of Claim 97 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

APAP31191-A 072852.0117
PATENT

101. (NEW) The method of Claim 97 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

102. (NEW) The method of Claim 97 wherein the oral liquid dosage form additionally comprises a least one additional agent.

103. (NEW) The method of Claim 102 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

02 cont
104. (NEW) A method for increasing the blood concentration of intact bile acid comprising;

- (a) administration of an oral liquid dosage form comprising:
 - (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
 - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product or an aqueous soluble non-starch polysaccharide; and
 - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

105. (NEW) The method of Claim 104 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

APAP31191-A 072852.0117
PATENT

12 cont

106. (NEW) The method of Claim 104 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursoodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

107. (NEW) The method of Claim 104 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

108. (NEW) The method of Claim 104 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

109. (NEW) The method of Claim 104 wherein the oral liquid dosage form additionally comprises at least one additional agent.

110. (NEW) The method of Claim 109 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

111. (NEW) A method for achieving a C_{max} (μ g UDCA/mL) of from about 4.5 to about 20.4 with a T_{max} of less than about 30 minutes comprising:

(a) administration of an oral liquid dosage form comprising:

APAP31191-A 072852.0117
PATENT

- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
- (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
- (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

12 cont
112. (NEW) The method of Claim 111 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

113. (NEW) The method of Claim 111 wherein the first material is selected from the group consisting of ursodeoxycholic acid, ursodeoxycholic acid derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, ursodeoxycholic acid salts, and ursodeoxycholic acid conjugates with amines.

114. (NEW) The method of Claim 111 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

115. (NEW) The method of Claim 111 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

116. (NEW) The method of Claim 111 wherein the oral liquid dosage form additionally comprises at least one additional agent.

APAP31191-A 072852.0117
PATENT

117. (NEW) The method of Claim 111 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

118. (NEW) The method of Claim 111 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount.

119. (NEW) The method of Claim 118 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, ampomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscarnet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- α , β , γ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir- H_2SO_4 , ritonavir, nelfinavir- CH_3SO_3H , saquinavir- CH_3SO_3H , d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomolate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyridamole, isoxsuprine-HCl, niacin, nylidin-HCl, phentolamine, doxazosin- CH_3SO_3H , prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidomine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythrytol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadil, albuterol, pirbuterol, terbutaline- H_2SO_4 , salmetrol, aminophylline, dyphylline, ephedrine, ethylnorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HIBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartrate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium

NY02:358466.1

Received from <212> at 1/8/02 3:00:11 PM [Eastern Standard Time]

APAP31191-A 072852.0117
PATENT

tartarate, glycerin, terpin-hydrate, colfasceril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, sirvastatin, picrorrhazia kurva, andrographis paniculata, mornga oleifera, albizzia lebeck, adhata vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO₃, miconazole, nystatin, oxiconazole-HNO₃, sulconazole-HNO₃, cetirizine-2HC1, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, ludrocortisone acetate, flunisolide, fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopudnol, piroxicam, toimelin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds insuline, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

(2) cont

120. (NEW) A method of increasing or decreasing absorption and elimination of intact bile acid comprising:

- (a) administration of an oral liquid dosage form comprising:
 - (i) a first material selected from the group consisting of a bile acid, and aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
 - (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
 - (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

APAP31191-A 072852.0117
PATENT

121. (NEW) The method of Claim 120 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

122. (NEW) The method of Claim 120 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, tauroursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursoodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

123. (NEW) The method of Claim 120 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

12 cont
124. (NEW) The method of Claim 120 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

125. (NEW) The method of Claim 120 wherein the oral liquid dosage form additionally comprises a least one additional agent.

126. (NEW) The method of Claim 125 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

127. (NEW) The method of Claim 120 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount.

APAP31191-A 072852.0117
PATENT

128. (NEW) The method of Claim 127 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotestosterone, ampomorphine, yohimbine, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, foscarnet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- α , β , γ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifluridine, valacyclovir-HCl, zalcitabine, zidovudine, indinavir-H₂SO₄, ritonavir, nelfinavir-CH₃SO₃H, saquinavir-CH₃SO₃H, d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HCl, minoxidil, dipyridamole, isoxsuprine.HCl, niacin, nyldihydro-HCl, phentolamine, doxazosin-CH₃SO₃H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidomine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythritol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadil, albuterol, pirbuterol, terbutaline-H₂SO₄, salmetrol, aminophylline, dyphylline, ephedrine, ethylnorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartrate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartarate, glycerin, terpin-hydrate, colfasceril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, simvastatin, picrorhiza kurvva, andrographis paniculata, moringa oleifera, albizzia lebeck, adhatoda vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinospora cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO₃, miconazole, nystatin, oxiconazole-HNO₃, sulconazole-HNO₃, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhizic acid, betamethasone, ludrocortisone acetate, flunisolide,

cont

APAP31191-A 072852.0117
PATENT

fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfinpyrazone, allopudnol, piroxicam, tometin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds insuline, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

129. (NEW) A method for achieving a C_{max} (μ g GUDCA/mL) of from about 0.3 to about 1.6 with a T_{max} of less than about 3.5 hours comprising:

(a) administration of an oral liquid dosage form comprising:

- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
- (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
- (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

130. (NEW) The method of Claim 129 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

131. (NEW) The method of Claim 111 wherein the first material is selected from the group consisting of glycoursoodeoxycholic acid, glycoursoodeoxycholic acid derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, glycoursoodeoxycholic acid salts, and glycoursoodeoxycholic acid conjugates with amines.

APAP31191-A 072852.0117
PATENT

132. (NEW) The method of Claim 129 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

133. (NEW) The method of Claim 129 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

134. (NEW) The method of Claim 129 wherein the oral liquid dosage form additionally comprises a least one additional agent.

135. (NEW) The method of Claim 134 wherein the additional agent is selected from the group consisting of guar gum, pectin, acacia, carrageenan, carboxymethyl cellulose sodium, hydroxymethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl alcohol, povidone, tragacanth gum, xanthan gum, and sorbitan ester.

(12 cont)

136. (NEW) The method of Claim 129 wherein the oral liquid dosage form additionally comprises at least one pharmaceutical in a pharmaceutically effective amount,

137. (NEW) The method of Claim 136 wherein the pharmaceutical compound is selected from the group consisting of octreotide, sildenafil citrate, calcitriol, dihydrotachysterol, ampomorphine, yohimbin, trazodone, acyclovir, cidofovir, delavirdine-mesylate, didanosine, famciclovir, forscamet sodium, fluorouracil, ganciclovir sodium, idoxuridine, interferon- α , β , γ , lamivudine, nevirapine, penciclovir, ribavirin, stavudine, trifludine, valacyclovir-HC1, zalcitabine, zidovudine, indinavir- H_2SO_4 , ritonavir, nelfinavir- CH_3SO_3H , saquinavir- CH_3SO_3H , d-penicillamine, chloroquine, hydroxychloroquine, aurothioglucose, gold sodium thiomalate, auranofin levamisole, DTC, isoprinosine, methyl inosine monophosphate, muramyl dipeptide, diazoxide, hydralazine-HC1, minoxidil, dipyridamole, isoxsuprine.HCl, niacin, nylidin-HCl,

APAP31191-A 072852.0117
PATENT

phentolamine, doxazosin-CH₃SO₃H, prazosin-HCl, terazocin-HCl, clonidine-HCl, nifedipine, molsidomine, amiodarone, acetylsalicylic acid, verapamil, diltiazem, nisoldipine, isradipine, bepridil, isosorbide-dinitrate, pentaerythrytol-tetranitrate, nitroglycerin, cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, omeprazole, misoprostol, sucralfate, metoclopramide-HCl, erythromycin, alprostadil, albuterol, pirbuterol, terbutaline-H₂SO₄, salmeterol, aminophylline, dyphylline, ephedrine, ethylnorepinephrine, isoetharine, isoproterenol, metaproterenol, n-docromil, oxy triphylline, theophylline, bitolterol, fenoterol, budesonide, flunisolide, beclomethasone-dipropionate, fluticasone-propionate, codeine, codeine sulfate, codeine phosphate, dextromethorphan.HBr, triamcinolone-acetonide, montelukast sodium, zafirlukast, zileuton, cromolyn sodium, ipratropium bromide, nedocromil sodium benzonate, diphenhydramine-HCl, hydrocodone-bitartrate, methadone-HCl, morphine sulfate, acetylcysteine, guaifenesin, ammonium carbonate, ammonium chloride, antimony potassium tartate, glycerin, terpin-hydrate, colfasceril palmitate, atorvastatin-calcium, cervastatin-sodium, fluvastatin-sodium, lovastatin, pravastatin-sodium, simvastatin, picrorhazia kurvva, andrographis paniculata, moringa oleifera, albizzia lebeck, adhatoda vasica, curcuma longa, momordica charantia, gymnema sylvestre, terminalia arjuna, azadirachta indica, tinosporia cordifolia, metronidazole, amphotericin B, clotrimazole, fluconazole, haloprogin, ketoconazole, griseofulvin, itraconazole, terbinafin-HCl, econazole-HNO₃, miconazole, nystatin, oxiconazole-HNO₃, sulconazole-HNO₃, cetirizine-2HCl, dexamethasone, hydrocortisone, prednisolone, cortisone, catechin and its derivatives, glycyrrhizin, glycyrrhetic acid, betamethasone, ludrocortisone acetate, flunisolide, fluticasone-propionate, methyl prednisolone, somastostatin, lispro, glucagon, acarbose, chlorpropamide, glipizide, glyburide, metformin-HCl, repaglinide, tolbutamide, colchicine, sulfapyrazone, allopudnol, piroxicam, tometin sodium, indomethacin, ibuprofen, diflunisal, mefenamic acid, naproxen, trientine, sulindac, sulindac sulfone, selenium compounds insulin, heparin, ampicillin, amantadine, rimantadine, proinsulin, celecoxib, budesonide, salicylic acid and its derivatives.

138. (NEW) A clear aqueous solution comprising;

NY02:358466.1

APAP31191-A 072852.0117
PATENT

Sub Bix C

- (i) a first material selected from the group consisting of a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, a bile acid conjugated with an amine by an amide linkage, and combinations thereof;
- (ii) a second material selected from the group consisting of an aqueous soluble starch conversion product and/or an aqueous soluble non-starch polysaccharide; and
- (iii) water,

wherein the first and second materials both remain in solution for all pH values of the solution within a selected range of pH values.

Frank

139. (NEW) The solution of Claim 138 wherein the dosage form is selected from the group consisting of a syrup, a thick syrup, and a paste.

140. (NEW) The solution of Claim 138 wherein the first material is selected from the group consisting of ursodeoxycholic acid, chenodeoxycholic acid, cholic acid, hyodeoxycholic acid, deoxycholic acid, 7-oxolithocholic acid, lithocholic acid, iododeoxycholic acid, iocholic acid, taoursodeoxycholic acid, taurochenodeoxycholic acid, taurodeoxycholic acid, glycoursoodeoxycholic acid, taurocholic acid, glycocholic acid, their derivatives at a hydroxyl or carboxylic acid group on the steroid nucleus, their salts, or their conjugates with amines.

141. (NEW) The solution of Claim 138 wherein the second material is selected from the group consisting of maltodextrin, dextrin, corn syrup, corn syrup solid, soluble starch, and dextrans.

142. (NEW) The solution of Claim 138 wherein the oral liquid dosage form comprises one or more additional bile acids, aqueous soluble derivatives of bile acid, bile acid salts, and amine-conjugated bile acids conjugated by an amide linkage.

APAP31191-A 072852.0117
PATENT

Sur
D10
12 cont.

143. (NEW) The solution of Claim 138 wherein the solution is capable of anti-inflammatory activity.

144. (NEW) The solution of Claim 138 wherein the solution is capable of analgesic activity.

145. (NEW) The solution of Claim 138 wherein the solution is capable of anticonvulsant activity.

146. (NEW) The solution of Claim 138 wherein the solution is capable of prolonging survival time in hypoxic conditions.

147. (NEW) The solution of Claim 138 wherein the solution is capable of alleviating or ameliorating stomatitis, gingivitis and toothache.